Clinical Pearls
- FL is the most common subtype of B-cell NHL (per WHO criteria), most common indolent lymphoma. Goal of therapy is palliative, considered as chronic disease with multiple recurrence. Median diagnosis age is 70 years.
- Evaluation: GELF, PE, ECOG, B symptoms (fever, night sweats, weight loss), CBC, CMP, LDH, HBV/HCV, PET/CT, bone marrow biopsy (if stage I-II ISRT or cytopenia), pregnancy, ECHO/MUGA (if anthracycline), β2-microglobulin, uric acid, SPEP or Ig levels.
- Differential diagnosis (BCL2-): dFL (pelvis/inguinal, STAT6, TNFRSF14), LBCL IRF4/MUM1 (peds, Waldeyer’s ring, aggressive), PTFL (peds, head/neck, indolent, curable)
- Prognostic Tools
- GELF (therapy indication): ≥3 nodal sites, large nodal/extranodal, B symptoms, spleen, lung, cytopenia, leukemia
- FLIPI (OS, mostly used): age ≥60, stage III-IV, hgb <12, LDH, ≥5 nodal areas. Low (0-1), intermediate (2), high (≥3)
- FLIPI-2 (PFS): Adds β2-microglobulin, marrow involvement, and max LN diameter (>6 cm).
- The strongest predictor of long-term outcomes is the length of first remission after first-line treatment.
- Grading by centroblasts/HPF, higher is more aggressive. Most are low grade (1-2); 3B is aggressive like DLBCL. cFL includes 1,2,3A.
- Genomics (CD10, CD20, BCL2, BCL6): BCL2 translocation [t(14;18), ≥85%], BCL2 mutation (12% FL, 53% FL transformation), CD23±, CD43-, CD5-.
- Rituximab monotherapy if elderly/frail, low tumor burden. Obinutuzumab if rituximab-refractory (PFS benefit). R2 is chemo-free.
- Localized (SI-II, G1-2) asymptomatic/nonbulky: ISRT, ISRT+antiCD20±chemo (FFS benefit, similar OS), antiCD20±chemo (if bulky intrabdominal, mesenteric SI), surveillance (if toxicity>benefit), systemic therapy (if symptomatic/bulky: R-CHOP, R-CVP, BR).
- Advanced Disease (Stage III-IV, G1-2)
- Asymptomatic, no indication (GELF): active surveillance (toxicity>benefit, per NCCN Guideline)
- Indication for systemic therapy: symptomatic, threatened end-organ function, cytopenia due to lymphoma, massive bulk or splenomegaly, steady progression over ≥ 6 months, autoimmune cytopenias, recurrent infections and/or patient preference.
- First-line therapy: [Obinutuzumab or Rituximab] + [Bendamustine, CHOP, CVP (CVP for anthracycline ineligible)],
R2 (chemo-free regimen), Rituximab alone (if low tumor burden; 375mg/m2/wk x4), G-Lena (categ. 2B); clinical trial- StiL NHL1 (BR vs R-CHOP): longer PFS and TTNT, fewer 2L and less AE (G3+ neutropenia).
- BRIGHT (BR vs R-CHOP or R-CVP): longer PFS and DOR.
- RELEVANCE (R2): similar CR, PFS, OS; lower G3+ neutropenia but higher G3+ cutaneous AE.
- GALLIUM (G-chemo vs R-chemo): longer PFS, higher infusion-related reaction and heme toxicity; higher mortality with Bendamustine (opportunistic infection, fatal infection, cardiac, neurologic, respiratory, secondary malignancy).
- First-line for elderly/imfirm: Rituximab alone (375 mg/m2/wk x4 doses), Chlorambucil±R, Cyclophosphamide±R.
- First-line consolidation or extended dosing (CR or PR): rituximab (if high tumor burden, previous RCVP/RCHOP, category 1, 375 mg/m2 q8-12wk x2yrs), Obinutuzumab alone [if previous G-chemo; 1g q8wk x12 doses (~2yrs), active surveillance
- PRIMA (Rituximab maintenance): longer PFS and at 10yr follow-up.
- Relapse/refractory FL
- Histologic transformation (2-3% per year, FDG-PET and re-biopsy recommended): suspected in rising LDH levels, single site growing disproportionally, extranodal, hypercalcemia, new B symptoms, non-response to initial therapy, or early relapse.
- BiTE (Epcoritamab-bysp, Glofitamab-gxbm after ≥2 lines)
- Early relapse (POD24; ~20%): recurrence/progression within 2y of initial chemoimmunotherapy; poor prognosis (5y OS 50%).
- Second-line and subsequent therapy: [Obinutuzumab or rituximab] + [Bendamustine, CHOP, CVP] (use Obinutuzumab if Rituximab refractory/progression within 6mo), R2, Tafasitamab+R2 (after ≥1 systemic including antiCD20; inMIND), Lenalidomide (if anti-CD20 ineligible), Obinutuzumab+Lena, Rituximab alone, Obinutuzumab alone
- GADOLIN (Benda+Obinu vs Benda): longer PFS; G3+ ADE neutropenia, thrombocytopenia, anemia, infusion-related reactions; lower treatment-related death (25% vs 42%)
- CALGB/Alliance 50401 (R2 vs Lenalidomide): higher ORR (76% vs 20%), CR (39% vs 20%), time to progression (2 vs 1.1yr); less ttt failure and more completes 12 cycles (63% vs 36%), G3+ ADE were neutropenia, fatigue, thrombosis
- GALEN (Lenalidomide+Obinutuzumab): ORR 79%, CR 33%, EFS 62%, PFS 65%, DOR 70%, OS 87%; ADE asthenia, neutropenia, bronchitis, diarrhea, muscle spasms; G3+ neutropenia; serious ADE with basal cell carcinoma, FN (1 death).
- Second-line and subsequent therapy for elderly/infirm: Rituximab (375 mg/m2/wk x4 doses), Tazemetostat (irrespective of EZH2 mutation), Cyclophosphamide±R.
- Second-line extended (CR or PR): Rituximab (375 mg/m2 q12wk x2y; category 1), Obinutuzumab (if Rituximab refractory; 1g q8wk x12 doses), active surveillance, BiTE (as 3L if PR), CAR-T (as 3L if PR)
- EORTIC 20981 (Rituximab vs observation): longer PFS, OS; higher G3+ infection
- Second-line consolidation: HD+autoSCT.
- Third-line and subsequent: 2L (if not used), BiTE (Epcoritamab, Mosunetuzumab), CAR T-cell (Yescarta, Breyanzi, Kymriah), Tazemetostat (irrespective of EZH2 mutation), BTKi (Zanubrutinib+Obinutuzumab), Loncastuximab teserine+R (category 2B)
- Budde 2022 (Mosunetuzumab): CR 60% (higher than Copanlisib 14%); DoCR was not estimable, 24-mo CR 65%; median PFS and OS was not estimable.
- Alderuccio 2025 (Lonca+Ritux): CR 67%; G3+ ADE lymphopenia, neutropenia; edema G1-2 managed with diuretics
- ROSEWOOD (Zanu+Obinu vs Obinu): higher ORR (69% vs 46%), CR (39% vs 19%), DOR (69% vs 42%), PFS (28 vs 10.4mo); ADE (ZO) was thrombocytopenia, neutropenia, diarrhea, fatigue; AF (3%), major hemorrhage (1%).
- ZUMA-5 (Yescarta): ORR 96%, CR 74%; G3+ ADE cytopenia 70%, infections 18%, CRS 7%, ICANS 19%;
serious ADE 50%; death 3%
- TRANSCEND FL (Breyanzi): ORR 97%, CR 94%; G3+ neutropenia, CRS 58% (G3+ 1%, onset 6d, duration 3d); ICANS 15% (G3+ 2%, onset 8.5d, resol. 3.5d); Tocilizumab (n=18, 14%); B-cell aplasia ≥95% at 2mo; 1 death (MAS)
- ELARA (Kymriah): ORR 86.2%, CR 69.1%; CRS 48.5% (G3+ 0%), neuro 37.1% (G3+ 3%), ICANS 4.1% (G3+ 1%)
- EPCORE NHL-1 (Epcoritamab-bysp): showed ORR 61% (CR 38%), median DOR 15.6mo.
- E7438-G000-101 (Tazemetostat; EZH2mut vs EZH2WT): ORR 69%v35%, DOR 10.9v13mo, PFS 13.8v11.1mo. Cytopenia
- Unclear if Tafasitamab, Loncastuximab, antiCD19 have negative impact on subsequent CAR T cell efficacy.
- Third-line consolidation: allo-SCT (if stem cell mobilization failures and persistent bone marrow involvement)
- Histologic transformation (2-3% per year, FDG-PET and re-biopsy recommended): suspected in rising LDH levels, single site growing disproportionally, extranodal, hypercalcemia, new B symptoms, non-response to initial therapy, or early relapse.
- Stage I-IV (G3A) treatment is controversial and should be individualized. Stage I-IV (G3B) treatment is per DLBCL guidelines.
- Follow-up: H&P and labs (q3–6mo x5y, then annually/clinically indicated), imaging (C/A/P CT with contrast q6mo x2y then annually)
- High-Risk Considerations
- Histologic Transformation to DLBCL/HGBL/BL (2-3% per year): FDG-PET (identify areas for transformation) and biopsy it. Treat as de novo DLBCL (R-CHOP ± CNS ppx if indicated).
- HGBL (DHT; MYC+BCL2): clinical trial, ISRT (localized), DA-R-EPOCH, R-CHOP (IPI<2), R-mini-CHOP (old/frail),
R-HyperCVAD or R-CODOX-M/R-IVAC (young/fit, no/minimal comorbidities)
- DLBCL or HGBL (MYC+BCL6): R-CHOP, Pola-R-CHP (IPI≥2), for low LVEF (DA-R-EPOCH, R-CDOP, R-CEOP, R-GCVP, R-CEPP), for old/frail (R-mini-CHOP, R-CDOP, R-GCVP, R-CEPP)
- Multiple prior therapies: ASCT eligible (R-CHOP, DHAP±R, GDP, ICE±R), ASCT ineligible (R-CHOP, Pola±BR, Tafa+Lena)
- HGBL (DHT; MYC+BCL2): clinical trial, ISRT (localized), DA-R-EPOCH, R-CHOP (IPI<2), R-mini-CHOP (old/frail),
- High-grade FL (FL3B, MYC/BCL2/BCL6 rearrangements, LBCL IRF4/MUM1): treat as aggressive lymphoma (R-CHOP preferred)
- Histologic Transformation to DLBCL/HGBL/BL (2-3% per year): FDG-PET (identify areas for transformation) and biopsy it. Treat as de novo DLBCL (R-CHOP ± CNS ppx if indicated).
- Fertility preservation: sperm banking, semen cryopreservation, IVF, ovarian tissue or oocyte cryopreservation.
- Supportive Care Considerations
- Infusion reaction (Rituximab, Obinutuzumab): APAP, dexamethasone, diphenhydramine
- TLS Prophylaxis (high tumor burden): Consider allopurinol/rasburicase
- Cardiotoxicity (Doxorubicin): monitor LVEF by ECHO/MUGA at baseline, then when needed.
- Neuropathy (Vincristine, Cisplatin): dose reduction/interruption if severe.
- CRS (Mosunetuzumab-axqb) at C1-2, C3+ is optional: APAP, dexamethasone, diphenhydramine.
- CRS (Epcoritamab, Glofitamab, CAR T): Obinutuzumab 1g IV (7d prior Glofitamab as CRS mitigation); premeds of APAP, diphenhydramine, dexamethasone (Epcoritamab, Glofitamab, CAR T-cell therapy)
- Anticoagulation prophylaxis (Lenalidomide)
- HSV prophylaxis (Bendamustine, prolonged steroids): acyclovir 400mg PO BID.
- PJP Prophylaxis (Bendamustine, prolonged steroids): TMP-SMX or Dapsone.
- HBV/HCV reactivation (Rituximab, Obinutuzumab): screening at baseline (sAg, HBc; eAg if highrisk factor; viral load if positive and GI consult), treat when needed. Entecavir or Tenofovir ppx if receiving rituximab.
- PI3K inhibitors (Copanlisib, duvelisib, idelalisib, umbralisib) were previously FDA approved but was later voluntarily withdrawn due to toxicity and unfavorable impact on OS; currently not recommended for R/R FL.
| Regimens | Medications |
| R-CHOP | Rituximab, Cyclophosphamide, doxorubicin (Hydroxydaunorubicin), vincristine (Oncovin), Prednisone |
| G-CHOP | Obinutuzumab (Gazyva), Cyclophosphamide, doxorubicin (Hydroxydaunorubicin), vincristine (Oncovin), Prednisone |
| R-CVP | Rituximab, Cyclophosphamide, Vincristine, Prednisone |
| G-CVP | Obinutuzumab (Gazyva), Cyclophosphamide, Vincristine, Prednisone |
| R-CEPP | Rituximab, Cyclophosphamide, Etoposide, Procarbazine, Prednisone |
| BR | Bendamustine, Rituximab |
| R2 or LR | Lenalidomide (Revlimid), Rituximab |
| DA-R-EPOCH | Dose-Adjusted Rituximab, Etoposide, Prednisone, vincristine (Oncovin), Cyclophosphamide, doxorubicin (Hydroxydaunorubicin) |
| R-HyperCVAD | Rituximab, Hyperfractionated (smaller doses but more frequent), Cyclophosphamide, Vincristine, doxorubicin (Adriamycin), Dexamethasone Alternating with rituximab, high-dose methotrexate and cytarabine |
| R-CODOX-M/R-IVAC | Rituximab, Cyclophosphamide, vincristine (Oncovin), DOXorubicin, Methotrexate (high-dose) Alternating with rituximab, ifosfamide, etoposide, cytarabine |
| R-mini-CHOP (for elderly and frail) | Rituximab 375 mg/m² D1, Cyclophosphamide 400 mg/m² D1, Doxorubicin 25 mg/m² D1 (Hydroxydaunorubicin), Vincristine 1 mg D1 (Oncovin), Prednisone 40 mg/m² D1–5 |